Search PubMed⌕ Search

Biomedical subjects

J Corman

Publications and source records attributed to J Corman.

At least 19 recordsLinked to original sources
PubMed2000

Prostate brachytherapy in patients with median lobe hyperplasia.

Our aim was to document the technical and clinical course of prostate brachytherapy patients with radiographic evidence of median lobe hyperplasia (MLH). Eight patients with MLH were identified during our routine brachytherapy practice, representing 9% of the 87 brachytherapy patients treated during a 6-month period. No effort was made to avoid brachytherapy in patients noted to have MLH on diagnostic work-up. Cystoscopic evaluation was not routinely performed. Postimplant axial computed tomographic (CT) images of the prostate were obtained at 0.5 cm intervals. Preimplant urinary obstructive symptoms were quantified by the criteria of the American Urologic Association (AUA). Each patient was contacted during the writing of this report to update postimplant morbidity information. There was no apparent association between the degree of MLH and preimplant prostate volume or AUA score. Intraoperatively, we were able to visualize MLH by transrectal ultrasound and did not notice any particular difficulty placing sources in the MLH tissue or migration of sources out of the tissue. The prescription isodose covered from 81% to 99% of the postimplant CT-defined target volume, achieving adequate dose to the median lobe tissue in all patients. Two of the eight patients developed acute, postimplant urinary retention. The first patient required intermittent self-catheterization for 3 months and then resumed spontaneous urination. MLH does not appear to be a strong contraindication to prostate brachytherapy, and prophylactic resection of hypertrophic tissue in such patients is probably not warranted. Int. J. Cancer (Radiat. Oncol. Invest.) 90, 152-156 (2000).

Aged↗
PubMed2000

Cystourethroscopic findings before and after prostate brachytherapy.

PURPOSE: To assess the role of cystourethroscopy in predicting the risk of postimplant urinary retention. MATERIALS AND METHODS: Fifteen unselected prostate brachytherapy patients implanted with 125I or 103Pd under spinal or general anesthesia were studied. Following induction of anesthesia, the patient was placed in the lithotomy position and cystourethroscopy performed using a 17 sheath and a 30 degrees lens. Irrigation pressure was 100-cm water. A photograph was taken from the level of the verumontanum. At completion of the implant procedure, a second cystourethroscopy was performed and another photograph taken. The degree of obstruction was rated using a 3-point scale. Each patient was contacted at the time of this report to update postimplant morbidity information with follow-up from 1 to 10 months. RESULTS: The patients' preimplant cystourethroscopic findings ranged from minimal to complete occlusion. There was no clear relationship between the American Urologic Association (AUA) score or preimplant prostate volume and the degree of obstruction. Nearly all patients had some increased physical obstruction following completion of the procedure, but only 8 of 14 patients had an increase in obstruction grade. Six patients were completely obstructed at the completion of the implant procedure, only one of whom developed urinary retention. CONCLUSIONS: Marked variability in cystourethroscopy findings do not appear to have a strong influence on the likelihood of postimplant urinary retention and are not a reliable predictor of retention.

Brachytherapy↗
PubMed1999

[Hypertrichosis and gingival hypertrophy regression in renal transplants following the substitution of cyclosporin by tacrolimus].

Gingival Hyperplasia (GH) and hypertrichosis (HT) are two sides effects associated with the usage of cyclosporine (CyA) but not with tacrolimus (FK 506). The aim of this study is to evaluate the efficacy and security of the conversion from CsA to FK 506 to treat those two complications. From August 1996 to May 1997, 15 patients (9 males, 6 females) aged from 23 to 63 years old (38 +/- 14, mean +/- SD) were switched from CsA to FK 506, 12 for GH, 2 for HT and one for combined presentation. FK 506 was first initiated at a dose of 0.15 mg/kg/day and then adjusted to a level target of 8 ng/ml. The conversion was done on an out patient basis at average 35 (5-83) months after transplantation. Patients were followed prospectively for 12 months. There was a significant reduction in GH in all patients within 3 months. Five out 13 patients had a complete resolution of GH within three months of conversion, 9/12 within 6 months and all by 12 months. HT resolved completely within 6 months. No rejection episode occurred and the serum creatinin remain stable over one year post conversion. Conversion from CsA to FK 506 is thus a safe and valid option to treat CsA induced GH and HT.

Adult↗
PubMed1996

Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2.

Expression of the human immunodeficiency virus type 1 (HIV) protease in cultured cells leads to apoptosis, preceded by cleavage of bcl-2, a key negative regulator of cell death. In contrast, a high level of bcl-2 protects cells in vitro and in vivo from the viral protease and prevents cell death following HIV infection of human lymphocytes, while reducing the yields of viral structural proteins, infectivity, and tumor necrosis factor alpha. We present a model for HIV replication in which the viral protease depletes the infected cells of bcl-2, leading to oxidative stress-dependent activation of NF kappa B, a cellular factor required for HIV transcription, and ultimately to cell death. Purified bcl-2 is cleaved by HIV protease between phenylalanine 112 and alanine 113. The results suggest a new option for HIV gene therapy; bcl-2 muteins that have noncleavable alterations surrounding the HIV protease cleavage site.

Animals↗
PubMed1995

Ureteropelvic junction repair: stent and vent.

PURPOSE: We report on a simple technique of how to stent and vent the anastomosis after ureteropelvic junction repair in children. MATERIALS AND METHODS: An 8F feeding tube housing a 4F ureteral catheter, each trimmed to different lengths, was used to stent a ureteropelvic junction anastomosis in a 3-year-old girl with 1 functional kidney. On postoperative day 7 the ureteral catheter was removed and a nephrostogram was performed via the remaining feeding tube, which could also function as a nephrostomy tube. RESULTS: The combined tubes were simply constructed, easily cared for during the postoperative period, served the purpose of stenting and could provide nephrostomy drainage if necessary. CONCLUSIONS: We recommend our stent and vent system in select cases of ureteropelvic junction repair.

Anastomosis, Surgical↗
PubMed1995

[Acute tubular necrosis in patients after kidney transplantation: associated factors and impact on functional survival of the graft].

Acute tubular necrosis (ATN) represents a serious problem in kidney transplantation. We have reviewed the causes and effects of ATN on kidney transplant patients treated in our hospital between June 1981 and December 1992. We analyzed 359 consecutive kidney transplants performed in 338 patients (213 male and 125 female). There were 311 first grafts. The actuarial functional graft survival (AFGS) was 85% at 1 year and 58.2% at 10 years. The incidence of long-term chronic rejection, the 1-year creatinine blood level (CBL) and the AFGS are summarized: [table: see text] The donor age and the PRA level were significantly correlated with ATN occurrence. ATN after transplantation was associated with a poorer function and survival of the kidney graft. Better donor and patient selection could decrease the occurrence of ATN, thus improving the graft outcome.

Canada↗
PubMed1991

[Development of organ transplantation in Quebec from 1985 to January 1990].

In Québec, the first organ transplantations have been realized in 1958. Several kidney transplant programs started at that time. Cardiac, liver, pancreas and lungs programs followed and reached a full development in the eighties when Cyclosporin became available. Today, there are 4 university transplant programs in Québec (McGill, Montréal, Laval and Sherbrooke) with a total of 7 kidney, 4 liver, 4 heart, 2 pancreas and 2 lungs centers. More than 2,900 transplantations have been realized. Since 1970, organ procurement and distribution is organized by a central agency called Québec-Transplant (previously Métro-transplantation). Organ donation is done on a voluntary basis as every where in North America. More than 90% of the organs comes from cadaveric donors and more than 90% of the relatives accept organ donation. 50% of the donors have deceased from head trauma and 50% from cerebral hemorrhage. In 1989, multi-organ harvesting has been realized in 64% of the donors. Despite efforts and progresses, the number of patients awaiting an organ transplant is steadily growing and outlast the number of available organs. It is hoped that maximal utilisation of the donors and growing exchanges at a national and international level will help to solve this crucial problem.

Heart Transplantation↗
PubMed1990

Simultaneous liver and whole pancreas harvesting in the multiorgan cadaveric donor.

Simultaneous harvesting of the liver and whole pancreas is usually not performed because it is believed that the shared vascular supply of both organs is incompatible with safe grafting. A careful review of the vascular anatomy, however, shows that simultaneous removal of the two organs is feasible, and a technique is described by which the liver is revascularized in the recipient through the celiac axis or the common hepatic artery and the pancreas is revascularized through the superior mesenteric and splenic arteries. When the vascular supply is abnormal, reconstruction of the vascular tree of one or both organs may be needed. The results of this technique used on 10 recipients are analysed.

Cadaver↗
PubMed1989

Clinical pancreas transplantation: a learning curve of its management.

In this evolving experience, acceptable patient and graft survival after PTX appear best secured by the use of whole duodenopancreatic grafts, enteric drainage, triple immunosuppression induced by OKT3, and the monitoring of postprandial blood glucose and serum amylase for detection of rejection.

Adult↗
PubMed1988

Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity.

A preparation of cyclosporine (CsA) in liposomes was tested in the rat to evaluate its effectiveness in reducing CsA nephrotoxicity. The drug was injected intravenously in unilaterally nephrectomized Lewis rats at a daily dose of 25 mg/kg for 14 days, either in a cremophore solution (eight rats) or in a preparation of liposomes (eight rats). Another group of four animals received the cremophore solution alone. Overall, rats treated with the CsA-liposome preparation had reduced toxicity, exhibiting better survival rates and less weight loss than those treated with the CsA-cremophore. Incorporating CsA into liposomes induced a statistically significant (p less than 0.05) reduction in the otherwise progressive increase of serum creatinine during week 2 of the experiment. Following administration of CsA-liposome preparation, epithelial cells of the proximal renal tubules appeared morphologically normal, without evidence of vacuolization, which is characteristic of CsA nephrotoxicity and was seen in the CsA-cremophore group. Although the exact mechanism is not clearly understood, it is likely that the tissue distribution of CsA, when incorporated into liposomes, is modified in favour of the reticuloendothelial cells, thereby sparing highly sensitive, but non-target organs such as the kidneys.

Animals↗